**GlucoTrack (NASDAQ:GCTK) to Present Continuous Blood Glucose Monitor at 2024 BioFuture Meeting**

GlucoTrack, Inc. (NASDAQ: GCTK), a Delaware corporation, recently disclosed in an 8-K filing its participation in the 2024 BioFuture Meeting. The event will feature over 100 forward-looking presentations, where the company will spotlight its continuous blood glucose monitor.

The press release issued on October 22, 2024, highlighted GlucoTrack’s involvement at the gathering. The details of the Press Release have been included in Exhibit 99.1 of the filing.

It’s worth noting that the information shared in this disclosure, comprising Exhibit 99.1, is not considered “filed” under Section 18 of the Securities Exchange Act of 1934. Furthermore, this information is not to be integrated by reference into any submission with the Securities and Exchange Commission, except as specifically noted in such a filing.

As per Item 9.01 of the filing, the company will provide access to the Press Release dated October 22, 2024, under Exhibit 99.1. Additionally, the Cover Page Interactive Data File, embedded within the inline XBRL document, is supplied in Exhibit 104.

Lastly, the report is signed by Paul Goode, the Chief Executive Officer of GlucoTrack, Inc., in compliance with the mandates of the Securities Exchange Act of 1934.

This article provides insights into GlucoTrack’s upcoming participation in the 2024 BioFuture Meeting and the showcasing of its continuous blood glucose monitor.

*Note: The financial details provided in this article are as per the official SEC filing by GlucoTrack (NASDAQ:GCTK). Investors are advised to conduct further research before making any financial decisions.*

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read GlucoTrack’s 8K filing here.

GlucoTrack Company Profile

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.